Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
What's the purpose of the trial?
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
There are 7 centers participating in this trial. Enter a location below to find the closet center.
Learn more about the experimental treatments being evaluated in this clinical trial.
- LP-118 is an orally bioavailable inhibitor of the anti-apoptotic proteins B-cell lymphoma-2 (Bcl-2) and Bcl-extra large (Bcl-XL).
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!